|
|
| Amiodarone in a Nutshell |
| |
| |
Markets |
| |
- Currently marketed under the brand name Cordarone for the treatment of life-threatening recurrent ventricular arrhythmia when patients have not responded to other available antiarrhythmics or when alternatives could not be tolerated
- We could potentially develop and market this product with a safer formulation using Captisol for solubilization rather than the currently used solvent system
|
| |
Product Advantages |
| |
- Amiodarone is currently available in an injectable formulation as well as an oral tablet
- The current injectable formulation utilizes a solvent system for solubilization, which is associated with a rapid decrease in blood pressure.
- We have developed Captisol-Enabled Amiodarone IV which does not contain the solvent system found in the current formulation
|
| |
Development Status |
| |
- Licensed exclusively to Prism Pharmaceuticals, Inc.
- Prism filed an NDA in 2008
|
| Updated: May 29, 2008 | |
